HHS Faces Backlash Over Controversial Guinea-Bissau Vaccine Trial and Africa CDC Clash

The article reports that a U.S. HHS-funded hepatitis B vaccine trial in Guinea-Bissau—budgeted at $1.6 million and enrolling 14,000 infants, with only half receiving the vaccine—has sparked ethics concerns and comparisons to the Tuskegee study; Africa CDC says the trial is not affiliated with the US CDC and claims it has been halted, while HHS asserts the study will proceed; the affair unfolds amid a broader WHO-Africa CDC collaboration and an anticipated press conference, keeping the situation in flux.